At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Closed 08-06 16:00:00 EDT
1.25
-0.01
-0.79%
盘后1.22
-0.03-2.21%
19:36 EDT
High1.32Low1.24Vol434.81K
Open1.25D1 Closing1.26Amplitude5.94%
Mkt Cap90.37MTradable Cap83.76MTotal Shares72.30M
T/O555.36KT/O Rate0.65%Tradable Shares67.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vaxart Q2 Revenue Falls on Lower Government Contract Income
Reuters  ·  04:19
Vaxart Q2 Revenue Falls on Lower Government Contract Income
Biomea Fusion price target lowered to $7 from $9 at Citizens
TIPRANKS  ·  03:25
Biomea Fusion price target lowered to $7 from $9 at Citizens
Biomea Fusion (BMEA) Gets a Buy from Oppenheimer
TIPRANKS  ·  08-06 20:57
Biomea Fusion (BMEA) Gets a Buy from Oppenheimer
PepGen Q2 Net Loss Narrows as Expenses Fall
Reuters  ·  08-06 19:52
PepGen Q2 Net Loss Narrows as Expenses Fall
Amylyx Pharmaceuticals Q2 Posts Higher than Expected Loss
Reuters  ·  08-06 19:26
Amylyx Pharmaceuticals Q2 Posts Higher than Expected Loss
Analyst Maintains Buy Rating on Biomea Fusion as Metabolic Pipeline Advances and $4 Price Target Remains Unchanged
TIPRANKS  ·  08-06 18:37
Analyst Maintains Buy Rating on Biomea Fusion as Metabolic Pipeline Advances and $4 Price Target Remains Unchanged
Biomea Fusion, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06 08:25
Biomea Fusion, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Benzinga Earnings  ·  08-06 06:11
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Biomea Fusion reports Q2 EPS (12c), consensus (23c)
TIPRANKS  ·  08-06 05:35
Biomea Fusion reports Q2 EPS (12c), consensus (23c)
Biomea Fusion Q2 Loss Narrows, Cash Runway into Q2 2027
Reuters  ·  08-06 04:47
Biomea Fusion Q2 Loss Narrows, Cash Runway into Q2 2027
Biomea Fusion Q2 Net Loss Narrows to $8.33 Million; R&D Expenses Fall 44.68% to $9.14 Million
Reuters  ·  08-06 04:41
Biomea Fusion Q2 Net Loss Narrows to $8.33 Million; R&D Expenses Fall 44.68% to $9.14 Million
Biomea Fusion Q2 Basic EPS USD -0.12
THOMSON REUTERS  ·  08-06 04:05
Biomea Fusion Q2 Basic EPS USD -0.12
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
GlobeNewswire  ·  08-06 04:05
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview
Reuters  ·  08-01
Biomea Fusion Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  07-31
Calendar of U.S. Earnings Expected in the Week Ahead
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)
TIPRANKS  ·  06-24
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)
TIPRANKS  ·  06-12
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)
Biomea Fusion shareholders elect two directors at annual meeting
Reuters  ·  06-11
Biomea Fusion shareholders elect two directors at annual meeting
Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained
TIPRANKS  ·  06-08
Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study
THOMSON REUTERS  ·  06-06
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--